Avalo Therapeutics AVTX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's enterprise value?
- Avalo Therapeutics (AVTX) reported enterprise value of $315.24M in Q1 2026.
- How has Avalo Therapeutics's enterprise value changed year-over-year?
- Avalo Therapeutics's enterprise value increased by 909.2% year-over-year, from -$38.96M to $315.24M.
- What is the long-term trend for Avalo Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Avalo Therapeutics's enterprise value has grown at a 6.1% compound annual growth rate (CAGR), from $232.8M to $313.63M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.